These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17439935)

  • 41. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 42. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival with first-line bosentan in patients with primary pulmonary hypertension.
    McLaughlin VV; Sitbon O; Badesch DB; Barst RJ; Black C; Galiè N; Rainisio M; Simonneau G; Rubin LJ
    Eur Respir J; 2005 Feb; 25(2):244-9. PubMed ID: 15684287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease.
    Schuuring MJ; Bouma BJ; Cordina R; Gatzoulis MA; Budts W; Mullen MP; Vis JC; Celermajer D; Mulder BJ
    Int J Cardiol; 2013 Mar; 164(1):106-10. PubMed ID: 21763017
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.
    Degano B; Yaïci A; Le Pavec J; Savale L; Jaïs X; Camara B; Humbert M; Simonneau G; Sitbon O
    Eur Respir J; 2009 Jan; 33(1):92-8. PubMed ID: 18799506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease.
    Vis JC; Duffels MG; Mulder P; de Bruin-Bon RH; Bouma BJ; Berger RM; Hoendermis ES; van Dijk AP; Mulder BJ
    Int J Cardiol; 2013 Mar; 164(1):64-9. PubMed ID: 21723630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
    Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS
    Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.
    Dhillon S; Keating GM
    Am J Cardiovasc Drugs; 2009; 9(5):331-50. PubMed ID: 19791841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.
    Savale L; Magnier R; Le Pavec J; Jaïs X; Montani D; O'Callaghan DS; Humbert M; Dingemanse J; Simonneau G; Sitbon O
    Eur Respir J; 2013 Jan; 41(1):96-103. PubMed ID: 22653773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
    Hiramoto Y; Shioyama W; Higuchi K; Arita Y; Kuroda T; Sakata Y; Nakaoka Y; Fujio Y; Yamauchi-Takihara K
    J Cardiol; 2009 Jun; 53(3):374-80. PubMed ID: 19477379
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.
    Ibrahim R; Granton JT; Mehta S
    Can Respir J; 2006; 13(8):415-20. PubMed ID: 17149459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial.
    Schuuring MJ; Vis JC; van Dijk AP; van Melle JP; Vliegen HW; Pieper PG; Sieswerda GT; de Bruin-Bon RH; Mulder BJ; Bouma BJ
    Eur J Heart Fail; 2013 Jun; 15(6):690-8. PubMed ID: 23361871
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).
    Ulrich S; Speich R; Domenighetti G; Geiser T; Aubert JD; Rochat T; Huber L; Treder U; Fischler M
    Swiss Med Wkly; 2007 Oct; 137(41-42):573-80. PubMed ID: 17990150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension.
    Chin KM; Kingman M; de Lemos JA; Warner JJ; Reimold S; Peshock R; Torres F
    Am J Cardiol; 2008 Jun; 101(11):1669-72. PubMed ID: 18489949
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
    Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
    J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome.
    Kaya MG; Lam YY; Erer B; Ayhan S; Vatankulu MA; Nurkalem Z; Meric M; Eren M; Eryol NK
    J Card Fail; 2012 May; 18(5):379-84. PubMed ID: 22555267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.